Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

医学 阿利罗库单抗 急性冠脉综合征 内科学 心肌梗塞 心脏病学 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Gregory G. Schwartz,Philippe Gabríel Steg,Michael Szarek,Deepak L. Bhatt,Vera Bittner,Rafael Díaz,Jay M. Edelberg,Shaun G. Goodman,Corinne Hanotin,Robert A. Harrington,J. Wouter Jukema,Guillaume Lecorps,Kenneth W. Mahaffey,Angèle Moryusef,Robert Pordy,Kirby Quintero,Matthew T. Roe,William J. Sasiela,Jean‐François Tamby,Pierluigi Tricoci
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:379 (22): 2097-2107 被引量:3470
标识
DOI:10.1056/nejmoa1801174
摘要

BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. RESULTS: The median duration of follow-up was 2.8 years. A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group). CONCLUSIONS: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Eric的应助被洛必达采纳,获得10
3秒前
无极微光的应助被洛必达采纳,获得20
3秒前
asfafaf完成签到 ,获得积分10
3秒前
山海不远发布了新的文献求助10
3秒前
3秒前
嘻嘻哈哈的应助被MST采纳,获得10
3秒前
悦耳筮的应助被DW采纳,获得50
3秒前
twootg完成签到,获得积分10
4秒前
思源的应助被jianglili采纳,获得10
4秒前
奇奇奇发布了新的文献求助10
4秒前
乐乐的应助被Lomungii采纳,获得30
5秒前
fei完成签到,获得积分10
5秒前
5秒前
脱羰甲酸发布了新的文献求助10
6秒前
7秒前
米花完成签到,获得积分10
8秒前
萝卜狗完成签到 ,获得积分10
10秒前
10秒前
初景发布了新的文献求助10
10秒前
kai发布了新的文献求助10
11秒前
逐暮发布了新的文献求助10
12秒前
alandan完成签到,获得积分10
13秒前
CHEN完成签到 ,获得积分10
13秒前
清秀的蚂蚁完成签到,获得积分10
14秒前
粱夏烟发布了新的文献求助10
15秒前
L10086完成签到,获得积分10
15秒前
betty完成签到,获得积分10
16秒前
18秒前
是真的不吃鱼完成签到,获得积分10
20秒前
共享精神的应助被科研通管家采纳,获得10
20秒前
今后的应助被科研通管家采纳,获得10
20秒前
21秒前
21秒前
小蘑菇的应助被科研通管家采纳,获得10
21秒前
21秒前
鲸落小小的应助被科研通管家采纳,获得10
21秒前
21秒前
bkagyin的应助被科研通管家采纳,获得10
21秒前
英俊的铭的应助被科研通管家采纳,获得10
21秒前
元吉的应助被科研通管家采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188353
求助须知:如何正确求助?哪些是违规求助? 9576169
关于积分的说明 21845860
捐赠科研通 7786410
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482235